Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome

被引:11
|
作者
Careaga, Milo [1 ,2 ,3 ]
Noyon, Tamanna [3 ]
Basuta, Kirin [4 ]
Van de Water, Judy [3 ,5 ]
Tassone, Flora [3 ,4 ]
Hagerman, Randi J. [3 ,6 ]
Ashwood, Paul [1 ,2 ,3 ]
机构
[1] Univ Calif Davis, Dept Med Microbiol & Immunol, Sacramento, CA 95817 USA
[2] Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Med Ctr, MIND Inst, Sacramento, CA 95817 USA
[4] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA USA
[5] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA USA
[6] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA
来源
JOURNAL OF NEUROINFLAMMATION | 2014年 / 11卷
关键词
Fragile x syndrome; Immune; Cytokine; Metabotropic glutamate receptor; MOUSE MODEL; EXPANDED ALLELES; GENE FMR-1; CGG REPEAT; ACTIVATION; MGLUR5; IDENTIFICATION; INFLAMMATION; PERFORMANCE; PROFILES;
D O I
10.1186/1742-2094-11-110
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Fragile X syndrome (FXS) is the leading cause of inheritable intellectual disability in male children, and is predominantly caused by a single gene mutation resulting in expanded trinucleotide CGG-repeats within the 5' untranslated region of the fragile X mental retardation (FMR1) gene. Reports have suggested the presence of immune dysregulation in FXS with evidence of altered plasma cytokine levels; however, no studies have directly assessed functional cellular immune responses in children with FXS. In order to ascertain if immune dysregulation is present in children with FXS, dynamic cellular responses to immune stimulation were examined. Methods: Peripheral blood mononuclear cells (PBMC) were from male children with FXS (n = 27) and from male aged-matched typically developing (TD) controls (n = 8). PBMC were cultured for 48 hours in media alone or with lipopolysaccharides (LPS; 1 mu g/mL) to stimulate the innate immune response or with phytohemagglutinin (PHA; 8 mu g/mL) to stimulate the adaptive T-cell response. Additionally, the group I mGluR agonist, DHPG, was added to cultures to ascertain the role of mGluR signaling in the immune response in subject with FXS. Supernatants were harvested and cytokine levels were assessed using Luminex multiplexing technology. Results: Children with FXS displayed similar innate immune response following challenge with LPS alone when compared with TD controls; however, when LPS was added in the presence of a group I mGluR agonist, DHPG, increased immune response were observed in children with FXS for a number of pro-inflammatory cytokines including IL-6 (P = 0.02), and IL-12p40 (P < 0.01). Following PHA stimulation, with or without DHPG, no significant differences between subjects with FXS and TD were seen. Conclusions: In unstimulated cultures, subjects with FXS did not display altered dynamic immune response to LPS or PHA alone; however, subjects with FXS showed an altered response to co-current stimulation of LPS and DHPG, such that subjects with FXS failed to inhibit production of pro-inflammatory cytokines, suggesting a role of group I mGluR signaling in innate immune responses in FXS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome
    Milo Careaga
    Tamanna Noyon
    Kirin Basuta
    Judy Van de Water
    Flora Tassone
    Randi J Hagerman
    Paul Ashwood
    Journal of Neuroinflammation, 11
  • [2] Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome
    Alexia M. Thomas
    Nghiem Bui
    Jennifer R. Perkins
    Lisa A. Yuva-Paylor
    Richard Paylor
    Psychopharmacology, 2012, 219 : 47 - 58
  • [3] Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome
    Thomas, Alexia M.
    Bui, Nghiem
    Perkins, Jennifer R.
    Yuva-Paylor, Lisa A.
    Paylor, Richard
    PSYCHOPHARMACOLOGY, 2012, 219 (01) : 47 - 58
  • [4] Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?
    Lohith, Talakad G.
    Osterweil, Emily K.
    Fujita, Masahiro
    Jenko, Kimberly J.
    Bear, Mark F.
    Innis, Robert B.
    MOLECULAR AUTISM, 2013, 4
  • [5] Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome
    Scharf, Sebastian H.
    Jaeschke, Georg
    Wettsteinl, Joseph G.
    Lindemann, Lothar
    CURRENT OPINION IN PHARMACOLOGY, 2015, 20 : 124 - 134
  • [6] Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?
    Talakad G Lohith
    Emily K Osterweil
    Masahiro Fujita
    Kimberly J Jenko
    Mark F Bear
    Robert B Innis
    Molecular Autism, 4
  • [7] Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome
    Thomas, Alexia M.
    Bui, Nghiem
    Graham, Deanna
    Perkins, Jennifer R.
    Yuva-Paylor, Lisa A.
    Paylor, Richard
    BEHAVIOURAL BRAIN RESEARCH, 2011, 223 (02) : 310 - 321
  • [8] Calmodulin activity regulates group I metabotropic glutamate receptor-mediated signal transduction and synaptic depression
    Sethna, Ferzin
    Zhang, Ming
    Kaphzan, Hanoch
    Klann, Eric
    Autio, Dawn
    Cox, Charles L.
    Wang, Hongbing
    JOURNAL OF NEUROSCIENCE RESEARCH, 2016, 94 (05) : 401 - 408
  • [9] Subchronic Administration and Combination Metabotropic Glutamate and GABAB Receptor Drug Therapy in Fragile X Syndrome
    Pacey, Laura K. K.
    Tharmalingam, Sujeenthar
    Hampson, David R.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (03) : 897 - 905
  • [10] MAVOGLURANT Metabotropic Glutamate mGlu5 Receptor Antagonist Treatment of Fragile X Syndrome Treatment of Dyskinesia
    Cole, P.
    DRUGS OF THE FUTURE, 2012, 37 (01) : 7 - 12